Increasing trend of workflow automation in pathology testing coupled increasing regulatory compliance stringency related to drug development and disease diagnosis are expected to provide lucrative growth platform to digital pathology systems market in coming eight years. Additionally, increasing advancements in the molecular diagnostics and demand for ADME toxicology studies are further expected to propel market growth. However, capital intensive nature and stringent approval norms pertaining to digital pathology expected to hurdle growth in near future.
To request a sample copy or view summary of this report, click the link below:
Digital pathology systems market is studied with respect to two segments such as technology and application. Disease diagnosis application emerged as the highest revenue generating segment owing to increasing prevalence of chronic diseases such as cancer, asthma etc. Drug discovery and development segment is also expected to register notable growth over the forecast period. Telepathology market segment is gaining popularity and is expected to gain market share.
To request a sample copy or view TOC of this report, click the link below:
Geographically, North America is expected to have the largest market share owing to increasing usage of companion diagnostics and presence of sophisticated healthcare infrastructure followed by Europe over the forecast period. Asia Pacific is expected to grow at a lucrative growth rate due to increasing disposable income coupled with increasing patient awareness levels in coming six years. Prominent industry players of this market are 3DHistech, Leica Biosystems, Mikroscan Technologies, Ventana Medical Systems, Definiens AG, Hamamatsu Photonics K.K., Indica Labs, Visiopharm and Philips Healthcare .The...